SCHEMBL23900461

SCHEMBL23900461

Cc1ncc(C(=O)O)c(=O)n1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
CHEK1 O14757 1/20 0.45
LIMK1 P53667 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42
GABRE P78334 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29208282 0.87 KDM4E (0.44) KDM4EALDH1A1GAAPKMCHEK1
SCHEMBL30086903 0.83 NNMT (0.41) KDM4EALDH1A1GABRPGABRDGABRA1
SCHEMBL23888705 0.77 HTT (0.44) KDM4EALDH1A1GAAPKMCHEK1
SCHEMBL23888694 0.74 CHEK1 (0.40) KDM4EALDH1A1GAAPKMCHEK1
SCHEMBL7996974 0.74 KMT2A (0.38) KDM4EALDH1A1GAAPKMDYRK1A
SCHEMBL13216909 0.73 ALDH1A1 (0.34) KDM4EALDH1A1CLK4KMT2AHPGD
SCHEMBL28147239 0.72 MEN1 (0.53) KDM4EALDH1A1CLK4KMT2AHPGD
SCHEMBL7233738 0.72 ALDH1A1 (0.40) KDM4EALDH1A1GAAPKMCHEK1
SCHEMBL23147426 0.71 NOTUM (0.52) KDM4EALDH1A1GAAPKMTDP1
SCHEMBL11559241 0.71 NOTUM (0.52) KDM4EALDH1A1GAAPKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LTD (CN) 2025-11-27 US disclosed
US-12435062-B2 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2025-10-07 US disclosed
CN-117777103-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-29 CN disclosed
CN-117720520-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 CN disclosed
CN-117720519-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2024-03-19 CN disclosed
CN-115315422-B Amide compound and application thereof 和记黄埔医药(上海)有限公司 2023-11-07 CN disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 US disclosed
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-06-08 US disclosed
EP-4126844-A1 AMIDE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-02-08 EP disclosed
CN-115315422-A Amide compound and application thereof 和记黄埔医药(上海)有限公司 2022-11-08 CN disclosed
WO-2021197276-A1 Amide compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174513-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, ASS1, NAT1 KDM4E 1449/4885ALDH1A1 610/4885GAA 374/4885
US-12435062-B2 Amide compounds and uses thereof ASNS, ASS1, NAT1 KDM4E 1449/4885ALDH1A1 610/4885GAA 374/4885
US-20250361223-A1 AMIDE COMPOUNDS AND USES THEREOF ASNS, NAT1, AADAC KDM4E 1690/4885ALDH1A1 585/4885GAA 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.